TVM Capital Life Science invests in disruptive life science innovations with a two-pronged strategy: financing early-stage therapeutics through a strategic partnership with Eli Lilly and investing in differentiated commercial-stage medtech, diagnostics, digital health, and late-stage therapeutics. The firm leverages AI-driven approaches in drug development and partners closely with portfolio companies to accelerate market adoption of transformative medical products.
Bevorzugte Reifephase für die erste Finanzierung.
Early-stage therapeutics, commercial-stage medtech, diagnostics, digital health, and late-stage therapeutics with a focus on AI-driven drug development
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (39)
Amy Kao
Amy Kao, PhD
Barbara Hauser
Bien Kiat Tan
Catello Somma
Dominique Larose
Dr. Alain Thibault
Dr. Axel Polack
Dr. Helmut M. Schuehsler

Dr. Hubert Birner

Dr. Luc Marengère
Dr. Schuehsler

